Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs. The move comes as companies work to build goodwill with President Donald Trump,

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the threat of drug import duties from the Trump administration.